Cidara Therapeutics Inc Total Liabilities
Cidara Therapeutics Inc total liabilities. Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) has total liabilities worth $96.26 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cidara Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cidara Therapeutics Inc (2012–2024)
Total liabilities of Cidara Therapeutics Inc from 2012 to 2024. This chart illustrates how Cidara Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Cidara Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Cidara Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Cidara Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huadong Medicine Co Ltd
SHE:000963
|
China | CN¥15.43 Billion |
|
Industrial Securities Co Ltd
SHG:601377
|
China | CN¥297.93 Billion |
|
Zhejiang Dahua Technology Co Ltd
SHE:002236
|
China | CN¥13.12 Billion |
|
New Gold Inc
TO:NGD
|
Canada | CA$1.27 Billion |
|
RATIONAL UN.ADR 1/ 1/20
F:RAA1
|
Germany | €217.93 Million |
|
GPT Group
AU:GPT
|
Australia | AU$6.30 Billion |
|
SODEXO S.A. ADR/ 1/5 EO 4
F:SJ70
|
Germany | €11.19 Billion |
|
Leader Harmonious Drive Systems Co Ltd
SHG:688017
|
China | CN¥471.27 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Cidara Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Cidara Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Cidara Therapeutics Inc Total Liabilities Ratios Explained
Cidara Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cidara Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cidara Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Cidara Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $51.49 Million | -31.57% |
| 2023-12-31 | $75.24 Million | +21.50% |
| 2022-12-31 | $61.92 Million | +15.21% |
| 2021-12-31 | $53.75 Million | +8.13% |
| 2020-12-31 | $49.71 Million | +59.63% |
| 2019-12-31 | $31.14 Million | +55.92% |
| 2018-12-31 | $19.97 Million | +3.54% |
| 2017-12-31 | $19.29 Million | +2.70% |
| 2016-12-31 | $18.78 Million | +209.85% |
| 2015-12-31 | $6.06 Million | +86.70% |
| 2014-12-31 | $3.25 Million | +103.06% |
| 2013-12-31 | $1.60 Million | +1898.75% |
| 2012-12-31 | $80.00K | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more